RE:Quarterly call transcriptsmdjbrown wrote: If you have time to go back and read the quarterly call transcripts back to 2020, there is a lot of good info directly from the execs.
Q2, 2023 ‘If and when our pharmaceutical partner is successful in their generic application to produce a generic Epidiolex and distribute it’…………………… Q3, 2023 “There are many other great commercial projects happening at MediPharm, including preparing for a CBD natural health product channel in Canada, preparing for future generic Epidiolex in the U.S. and growing our clinical study business.” https://www.alphaspread.com/security/tsx/labs/earnings-calls/q4-2023
They can state they are preparing for Epidiolex launch all they'd like, but facts are facts, the ANDA associated with that is going nowhere until the patent litigation is settled (positively). If negative, it goes nowhere, if positive it may well take a fair bit more time to even get FDA approval, let alone start with production.
It would be a (very) nice thing to have obviously, but if anyone is hanging their hat on Epidiolex winning the day for LABS, then I suggest you place your money elsewhere since that's about as much as a gamble as anything in the markets today.
Fundamentally LABS is sound and strong, but they need to grow and execute without Epidiolex because that is just a pipe dream at this point.